Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Japan Generic Drugs Market by Product Type (Generic Prescription Medicines, Super Generics, Biosimilars), by Application (Cardiovascular Products, Anti-Infective Drugs, Anti-Arthritis Drugs, Central Nervous System Drugs, Anti-Cancer Drug, Respiratory Products, Others) and by Distribution Channel (Hospitals, Pharmacies, Private Clinics, Drug Stores, Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

A03804

Pages: NA

Charts: NA

Tables: NA

Generic drugs are pharmaceutical drugs with similar chemical makeup of a branded drug. Generic drugs are cheaper in Japan and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations of Japan; the Japanese Government has observed the growth of the generic drug market as imperative to Japans long-term economic health.

The major factors that contribute to the growth of the Japan generic drugs market include increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, rising costs of branded medicines, growth in geriatric population, increasing healthcare expenditure, and high demand for generic medicines. However, issues such as the consistency and stability of generic drugs in Japan and lower reimbursement fees are expected to restrain the market development. Development of reliable & stable new product launch, support from the government, and adoption of mergers & acquisition strategies to launch new products by key vendors contribute to significant demand for generic drugs in the near future.

The Japan generic drugs market is segmented on the basis of product type, application, and distribution channel. On the basis of product type, the market is segmented into generic prescription medicines, super generics, and biosimilars. Based on application the market is divided into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. On the basis of distribution channel, the market is segmented into hospitals, pharmacies, private clinics, drug stores, retail pharmacies, and others.

The key players that operate in this market include Teva Pharmaceutical Industries Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Sawai Pharmaceuticals Co., Ltd., NIPRO Medical Corporation, Meiji Seika Pharma Co., Ltd., Towa Pharmaceutical Co., Ltd., Hikari Pharmaceutical Co., Ltd., Fuji Pharma Co., Ltd., Mylan N.V., and GlaxoSmithKline Plc.

Key Benefits

  • The study provides an in-depth analysis of the Japan generic drugs market with current trends and future estimations to elucidate imminent investment pockets.
  • The report provides information about the current and upcoming trends in the Japan generic drugs market from 2016 to 2023, which helps determine prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict the growth of the Japan generic drugs market has been provided.
  • Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market have been provided.
  • Key market players within the market have been profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the Japan generic drugs market.

Japan Generic Drugs Market Key Segments:

By Product Type

  • Generic Prescription Medicines
  • Super Generics
  • Biosimilars

By Application

  • Cardiovascular Products
  • Anti-Infective Drugs
  • Anti-Arthritis Drugs
  • Central Nervous System Drugs
  • Anti-Cancer Drug
  • Respiratory Products
  • Others

By Distribution Channel

  • Hospitals
  • Pharmacies
  • Private Clinics
  • Drug Stores
  • Retail Pharmacies
  • Others

 Key Market Segments

  • By Product Type
    • Generic Prescription Medicines
    • Super Generics
    • Biosimilars
  • By Application
    • Cardiovascular Products
    • Anti-Infective Drugs
    • Anti-Arthritis Drugs
    • Central Nervous System Drugs
    • Anti-Cancer Drug
    • Respiratory Products
    • Others
  • By Distribution Channel
    • Hospitals
    • Pharmacies
    • Private Clinics
    • Drug Stores
    • Retail Pharmacies
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Hikari Pharmaceutical Co., Ltd.
  • NIPRO Medical Corporation
  • Towa Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • GlaxoSmithKline Plc.
  • Nichi-Iko Pharmaceutical Co., Ltd.
  • Fuji Pharma Co., Ltd.
  • Sawai Pharmaceuticals Co., Ltd.
  • Meiji Seika Pharma Co., Ltd.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: JAPAN GENERIC DRUGS MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Generic Prescription Medicines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Super Generics

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Biosimilars

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

  • CHAPTER 5: JAPAN GENERIC DRUGS MARKET, BY APPLICATION

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Application

    • 5.2. Cardiovascular Products

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Anti-Infective Drugs

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Anti-Arthritis Drugs

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Central Nervous System Drugs

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Anti-Cancer Drug

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Respiratory Products

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

    • 5.8. Others

      • 5.8.1. Key Market Trends, Growth Factors and Opportunities

      • 5.8.2. Market Size and Forecast, By Region

      • 5.8.3. Market Share Analysis, By Country

  • CHAPTER 6: JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Distribution Channel

    • 6.2. Hospitals

      • 6.2.1. Key Market Trends, Growth Factors and Opportunities

      • 6.2.2. Market Size and Forecast, By Region

      • 6.2.3. Market Share Analysis, By Country

    • 6.3. Pharmacies

      • 6.3.1. Key Market Trends, Growth Factors and Opportunities

      • 6.3.2. Market Size and Forecast, By Region

      • 6.3.3. Market Share Analysis, By Country

    • 6.4. Private Clinics

      • 6.4.1. Key Market Trends, Growth Factors and Opportunities

      • 6.4.2. Market Size and Forecast, By Region

      • 6.4.3. Market Share Analysis, By Country

    • 6.5. Drug Stores

      • 6.5.1. Key Market Trends, Growth Factors and Opportunities

      • 6.5.2. Market Size and Forecast, By Region

      • 6.5.3. Market Share Analysis, By Country

    • 6.6. Retail Pharmacies

      • 6.6.1. Key Market Trends, Growth Factors and Opportunities

      • 6.6.2. Market Size and Forecast, By Region

      • 6.6.3. Market Share Analysis, By Country

    • 6.7. Others

      • 6.7.1. Key Market Trends, Growth Factors and Opportunities

      • 6.7.2. Market Size and Forecast, By Region

      • 6.7.3. Market Share Analysis, By Country

  • CHAPTER 7: JAPAN GENERIC DRUGS MARKET, BY REGION

    • 7.1. Market Overview

      • 7.1.1 Market Size and Forecast, By Region

    • 7.2. North America

      • 7.2.1. Key Market Trends and Opportunities

      • 7.2.2. Market Size and Forecast, By Product Type

      • 7.2.3. Market Size and Forecast, By Application

      • 7.2.4. Market Size and Forecast, By Distribution Channel

      • 7.2.5. Market Size and Forecast, By Country

      • 7.2.6. U.S.

        • 7.2.6.1 Market size and forecast, product type

        • 7.2.6.2 Market size and forecast, application

        • 7.2.6.3 Market size and forecast, distribution channel

      • 7.2.7. Canada

        • 7.2.7.1 Market size and forecast, product type

        • 7.2.7.2 Market size and forecast, application

        • 7.2.7.3 Market size and forecast, distribution channel

      • 7.2.8. Mexico

        • 7.2.8.1 Market size and forecast, product type

        • 7.2.8.2 Market size and forecast, application

        • 7.2.8.3 Market size and forecast, distribution channel

    • 7.3. Europe

      • 7.3.1. Key Market Trends and Opportunities

      • 7.3.2. Market Size and Forecast, By Product Type

      • 7.3.3. Market Size and Forecast, By Application

      • 7.3.4. Market Size and Forecast, By Distribution Channel

      • 7.3.5. Market Size and Forecast, By Country

      • 7.3.6. France

        • 7.3.6.1 Market size and forecast, product type

        • 7.3.6.2 Market size and forecast, application

        • 7.3.6.3 Market size and forecast, distribution channel

      • 7.3.7. Germany

        • 7.3.7.1 Market size and forecast, product type

        • 7.3.7.2 Market size and forecast, application

        • 7.3.7.3 Market size and forecast, distribution channel

      • 7.3.8. Italy

        • 7.3.8.1 Market size and forecast, product type

        • 7.3.8.2 Market size and forecast, application

        • 7.3.8.3 Market size and forecast, distribution channel

      • 7.3.9. Spain

        • 7.3.9.1 Market size and forecast, product type

        • 7.3.9.2 Market size and forecast, application

        • 7.3.9.3 Market size and forecast, distribution channel

      • 7.3.10. UK

        • 7.3.10.1 Market size and forecast, product type

        • 7.3.10.2 Market size and forecast, application

        • 7.3.10.3 Market size and forecast, distribution channel

      • 7.3.11. Russia

        • 7.3.11.1 Market size and forecast, product type

        • 7.3.11.2 Market size and forecast, application

        • 7.3.11.3 Market size and forecast, distribution channel

      • 7.3.12. Rest Of Europe

        • 7.3.12.1 Market size and forecast, product type

        • 7.3.12.2 Market size and forecast, application

        • 7.3.12.3 Market size and forecast, distribution channel

    • 7.4. Asia-Pacific

      • 7.4.1. Key Market Trends and Opportunities

      • 7.4.2. Market Size and Forecast, By Product Type

      • 7.4.3. Market Size and Forecast, By Application

      • 7.4.4. Market Size and Forecast, By Distribution Channel

      • 7.4.5. Market Size and Forecast, By Country

      • 7.4.6. China

        • 7.4.6.1 Market size and forecast, product type

        • 7.4.6.2 Market size and forecast, application

        • 7.4.6.3 Market size and forecast, distribution channel

      • 7.4.7. Japan

        • 7.4.7.1 Market size and forecast, product type

        • 7.4.7.2 Market size and forecast, application

        • 7.4.7.3 Market size and forecast, distribution channel

      • 7.4.8. India

        • 7.4.8.1 Market size and forecast, product type

        • 7.4.8.2 Market size and forecast, application

        • 7.4.8.3 Market size and forecast, distribution channel

      • 7.4.9. South Korea

        • 7.4.9.1 Market size and forecast, product type

        • 7.4.9.2 Market size and forecast, application

        • 7.4.9.3 Market size and forecast, distribution channel

      • 7.4.10. Australia

        • 7.4.10.1 Market size and forecast, product type

        • 7.4.10.2 Market size and forecast, application

        • 7.4.10.3 Market size and forecast, distribution channel

      • 7.4.11. Thailand

        • 7.4.11.1 Market size and forecast, product type

        • 7.4.11.2 Market size and forecast, application

        • 7.4.11.3 Market size and forecast, distribution channel

      • 7.4.12. Malaysia

        • 7.4.12.1 Market size and forecast, product type

        • 7.4.12.2 Market size and forecast, application

        • 7.4.12.3 Market size and forecast, distribution channel

      • 7.4.13. Indonesia

        • 7.4.13.1 Market size and forecast, product type

        • 7.4.13.2 Market size and forecast, application

        • 7.4.13.3 Market size and forecast, distribution channel

      • 7.4.14. Rest of Asia Pacific

        • 7.4.14.1 Market size and forecast, product type

        • 7.4.14.2 Market size and forecast, application

        • 7.4.14.3 Market size and forecast, distribution channel

    • 7.5. LAMEA

      • 7.5.1. Key Market Trends and Opportunities

      • 7.5.2. Market Size and Forecast, By Product Type

      • 7.5.3. Market Size and Forecast, By Application

      • 7.5.4. Market Size and Forecast, By Distribution Channel

      • 7.5.5. Market Size and Forecast, By Country

      • 7.5.6. Brazil

        • 7.5.6.1 Market size and forecast, product type

        • 7.5.6.2 Market size and forecast, application

        • 7.5.6.3 Market size and forecast, distribution channel

      • 7.5.7. South Africa

        • 7.5.7.1 Market size and forecast, product type

        • 7.5.7.2 Market size and forecast, application

        • 7.5.7.3 Market size and forecast, distribution channel

      • 7.5.8. Saudi Arabia

        • 7.5.8.1 Market size and forecast, product type

        • 7.5.8.2 Market size and forecast, application

        • 7.5.8.3 Market size and forecast, distribution channel

      • 7.5.9. UAE

        • 7.5.9.1 Market size and forecast, product type

        • 7.5.9.2 Market size and forecast, application

        • 7.5.9.3 Market size and forecast, distribution channel

      • 7.5.10. Argentina

        • 7.5.10.1 Market size and forecast, product type

        • 7.5.10.2 Market size and forecast, application

        • 7.5.10.3 Market size and forecast, distribution channel

      • 7.5.11. Rest of LAMEA

        • 7.5.11.1 Market size and forecast, product type

        • 7.5.11.2 Market size and forecast, application

        • 7.5.11.3 Market size and forecast, distribution channel

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top Winning Strategies

    • 8.3. Product Mapping Of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top Player Positioning,2022

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Teva Pharmaceutical Industries Ltd.

      • 9.1.1. Company Overview

      • 9.1.2. Key Executives

      • 9.1.3. Company Snapshot

      • 9.1.4. Operating Business Segments

      • 9.1.5. Product Portfolio

      • 9.1.6. Business Performance

      • 9.1.7. Key Strategic Moves and Developments

    • 9.2. Nichi-Iko Pharmaceutical Co., Ltd.

      • 9.2.1. Company Overview

      • 9.2.2. Key Executives

      • 9.2.3. Company Snapshot

      • 9.2.4. Operating Business Segments

      • 9.2.5. Product Portfolio

      • 9.2.6. Business Performance

      • 9.2.7. Key Strategic Moves and Developments

    • 9.3. Sawai Pharmaceuticals Co., Ltd.

      • 9.3.1. Company Overview

      • 9.3.2. Key Executives

      • 9.3.3. Company Snapshot

      • 9.3.4. Operating Business Segments

      • 9.3.5. Product Portfolio

      • 9.3.6. Business Performance

      • 9.3.7. Key Strategic Moves and Developments

    • 9.4. NIPRO Medical Corporation

      • 9.4.1. Company Overview

      • 9.4.2. Key Executives

      • 9.4.3. Company Snapshot

      • 9.4.4. Operating Business Segments

      • 9.4.5. Product Portfolio

      • 9.4.6. Business Performance

      • 9.4.7. Key Strategic Moves and Developments

    • 9.5. Meiji Seika Pharma Co., Ltd.

      • 9.5.1. Company Overview

      • 9.5.2. Key Executives

      • 9.5.3. Company Snapshot

      • 9.5.4. Operating Business Segments

      • 9.5.5. Product Portfolio

      • 9.5.6. Business Performance

      • 9.5.7. Key Strategic Moves and Developments

    • 9.6. Towa Pharmaceutical Co., Ltd.

      • 9.6.1. Company Overview

      • 9.6.2. Key Executives

      • 9.6.3. Company Snapshot

      • 9.6.4. Operating Business Segments

      • 9.6.5. Product Portfolio

      • 9.6.6. Business Performance

      • 9.6.7. Key Strategic Moves and Developments

    • 9.7. Hikari Pharmaceutical Co., Ltd.

      • 9.7.1. Company Overview

      • 9.7.2. Key Executives

      • 9.7.3. Company Snapshot

      • 9.7.4. Operating Business Segments

      • 9.7.5. Product Portfolio

      • 9.7.6. Business Performance

      • 9.7.7. Key Strategic Moves and Developments

    • 9.8. Fuji Pharma Co., Ltd.

      • 9.8.1. Company Overview

      • 9.8.2. Key Executives

      • 9.8.3. Company Snapshot

      • 9.8.4. Operating Business Segments

      • 9.8.5. Product Portfolio

      • 9.8.6. Business Performance

      • 9.8.7. Key Strategic Moves and Developments

    • 9.9. Mylan N.V.

      • 9.9.1. Company Overview

      • 9.9.2. Key Executives

      • 9.9.3. Company Snapshot

      • 9.9.4. Operating Business Segments

      • 9.9.5. Product Portfolio

      • 9.9.6. Business Performance

      • 9.9.7. Key Strategic Moves and Developments

    • 9.10. GlaxoSmithKline Plc.

      • 9.10.1. Company Overview

      • 9.10.2. Key Executives

      • 9.10.3. Company Snapshot

      • 9.10.4. Operating Business Segments

      • 9.10.5. Product Portfolio

      • 9.10.6. Business Performance

      • 9.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL JAPAN GENERIC DRUGS MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. JAPAN GENERIC DRUGS MARKET FOR GENERIC PRESCRIPTION MEDICINES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. JAPAN GENERIC DRUGS MARKET FOR SUPER GENERICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. JAPAN GENERIC DRUGS MARKET FOR BIOSIMILARS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL JAPAN GENERIC DRUGS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 6. JAPAN GENERIC DRUGS MARKET FOR CARDIOVASCULAR PRODUCTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. JAPAN GENERIC DRUGS MARKET FOR ANTI-INFECTIVE DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. JAPAN GENERIC DRUGS MARKET FOR ANTI-ARTHRITIS DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. JAPAN GENERIC DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM DRUGS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. JAPAN GENERIC DRUGS MARKET FOR ANTI-CANCER DRUG, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. JAPAN GENERIC DRUGS MARKET FOR RESPIRATORY PRODUCTS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. JAPAN GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. GLOBAL JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 14. JAPAN GENERIC DRUGS MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. JAPAN GENERIC DRUGS MARKET FOR PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 16. JAPAN GENERIC DRUGS MARKET FOR PRIVATE CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 17. JAPAN GENERIC DRUGS MARKET FOR DRUG STORES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 18. JAPAN GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. JAPAN GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 20. JAPAN GENERIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 21. NORTH AMERICA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. NORTH AMERICA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. NORTH AMERICA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. NORTH AMERICA JAPAN GENERIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 25. U.S. JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. U.S. JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. U.S. JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 28. CANADA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 29. CANADA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 30. CANADA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 31. MEXICO JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. MEXICO JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. MEXICO JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. EUROPE JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. EUROPE JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. EUROPE JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. EUROPE JAPAN GENERIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 38. FRANCE JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. FRANCE JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 40. FRANCE JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 41. GERMANY JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 42. GERMANY JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 43. GERMANY JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 44. ITALY JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. ITALY JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 46. ITALY JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 47. SPAIN JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 48. SPAIN JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 49. SPAIN JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 50. UK JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. UK JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 52. UK JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 53. RUSSIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. RUSSIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. RUSSIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. REST OF EUROPE JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. REST OF EUROPE JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. REST OF EUROPE JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. ASIA-PACIFIC JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. ASIA-PACIFIC JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. ASIA-PACIFIC JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. ASIA-PACIFIC JAPAN GENERIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 63. CHINA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. CHINA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 65. CHINA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 66. JAPAN JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 67. JAPAN JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 68. JAPAN JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 69. INDIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. INDIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 71. INDIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 72. SOUTH KOREA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 73. SOUTH KOREA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 74. SOUTH KOREA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 75. AUSTRALIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. AUSTRALIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. AUSTRALIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. THAILAND JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. THAILAND JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. THAILAND JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. MALAYSIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. MALAYSIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. MALAYSIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. INDONESIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. INDONESIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. INDONESIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. REST OF ASIA PACIFIC JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. REST OF ASIA PACIFIC JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. REST OF ASIA PACIFIC JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. LAMEA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 91. LAMEA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 92. LAMEA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 93. LAMEA JAPAN GENERIC DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 94. BRAZIL JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. BRAZIL JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. BRAZIL JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. SOUTH AFRICA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. SOUTH AFRICA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. SOUTH AFRICA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. SAUDI ARABIA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. SAUDI ARABIA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. SAUDI ARABIA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. UAE JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 104. UAE JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 105. UAE JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 106. ARGENTINA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 107. ARGENTINA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 108. ARGENTINA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 109. REST OF LAMEA JAPAN GENERIC DRUGS, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 110. REST OF LAMEA JAPAN GENERIC DRUGS, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 111. REST OF LAMEA JAPAN GENERIC DRUGS, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 112. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 113. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 114. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
  • TABLE 115. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 116. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. NICHI-IKO PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 118. NICHI-IKO PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 119. NICHI-IKO PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 120. NICHI-IKO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 121. NICHI-IKO PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. SAWAI PHARMACEUTICALS CO., LTD.: KEY EXECUTIVES
  • TABLE 123. SAWAI PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT
  • TABLE 124. SAWAI PHARMACEUTICALS CO., LTD.: OPERATING SEGMENTS
  • TABLE 125. SAWAI PHARMACEUTICALS CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 126. SAWAI PHARMACEUTICALS CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 127. NIPRO MEDICAL CORPORATION: KEY EXECUTIVES
  • TABLE 128. NIPRO MEDICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 129. NIPRO MEDICAL CORPORATION: OPERATING SEGMENTS
  • TABLE 130. NIPRO MEDICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 131. NIPRO MEDICAL CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 132. MEIJI SEIKA PHARMA CO., LTD.: KEY EXECUTIVES
  • TABLE 133. MEIJI SEIKA PHARMA CO., LTD.: COMPANY SNAPSHOT
  • TABLE 134. MEIJI SEIKA PHARMA CO., LTD.: OPERATING SEGMENTS
  • TABLE 135. MEIJI SEIKA PHARMA CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 136. MEIJI SEIKA PHARMA CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 137. TOWA PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 138. TOWA PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 139. TOWA PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 140. TOWA PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 141. TOWA PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 142. HIKARI PHARMACEUTICAL CO., LTD.: KEY EXECUTIVES
  • TABLE 143. HIKARI PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT
  • TABLE 144. HIKARI PHARMACEUTICAL CO., LTD.: OPERATING SEGMENTS
  • TABLE 145. HIKARI PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 146. HIKARI PHARMACEUTICAL CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 147. FUJI PHARMA CO., LTD.: KEY EXECUTIVES
  • TABLE 148. FUJI PHARMA CO., LTD.: COMPANY SNAPSHOT
  • TABLE 149. FUJI PHARMA CO., LTD.: OPERATING SEGMENTS
  • TABLE 150. FUJI PHARMA CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 151. FUJI PHARMA CO., LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 152. MYLAN N.V.: KEY EXECUTIVES
  • TABLE 153. MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 154. MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 155. MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 156. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 157. GLAXOSMITHKLINE PLC.: KEY EXECUTIVES
  • TABLE 158. GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
  • TABLE 159. GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
  • TABLE 160. GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
  • TABLE 161. GLAXOSMITHKLINE PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL JAPAN GENERIC DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL JAPAN GENERIC DRUGS MARKET
  • FIGURE 3. SEGMENTATION JAPAN GENERIC DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN JAPAN GENERIC DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALJAPAN GENERIC DRUGS MARKET
  • FIGURE 11. JAPAN GENERIC DRUGS MARKET SEGMENTATION, BY PRODUCT TYPE
  • FIGURE 12. JAPAN GENERIC DRUGS MARKET FOR GENERIC PRESCRIPTION MEDICINES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. JAPAN GENERIC DRUGS MARKET FOR SUPER GENERICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. JAPAN GENERIC DRUGS MARKET FOR BIOSIMILARS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. JAPAN GENERIC DRUGS MARKET SEGMENTATION, BY APPLICATION
  • FIGURE 16. JAPAN GENERIC DRUGS MARKET FOR CARDIOVASCULAR PRODUCTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. JAPAN GENERIC DRUGS MARKET FOR ANTI-INFECTIVE DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. JAPAN GENERIC DRUGS MARKET FOR ANTI-ARTHRITIS DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. JAPAN GENERIC DRUGS MARKET FOR CENTRAL NERVOUS SYSTEM DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. JAPAN GENERIC DRUGS MARKET FOR ANTI-CANCER DRUG, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. JAPAN GENERIC DRUGS MARKET FOR RESPIRATORY PRODUCTS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. JAPAN GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. JAPAN GENERIC DRUGS MARKET SEGMENTATION, BY DISTRIBUTION CHANNEL
  • FIGURE 24. JAPAN GENERIC DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 25. JAPAN GENERIC DRUGS MARKET FOR PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 26. JAPAN GENERIC DRUGS MARKET FOR PRIVATE CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 27. JAPAN GENERIC DRUGS MARKET FOR DRUG STORES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 28. JAPAN GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 29. JAPAN GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: JAPAN GENERIC DRUGS MARKET
  • FIGURE 36. TOP PLAYER POSITIONING,2022
  • FIGURE 37. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. NICHI-IKO PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. NICHI-IKO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. NICHI-IKO PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. SAWAI PHARMACEUTICALS CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. SAWAI PHARMACEUTICALS CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. SAWAI PHARMACEUTICALS CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. NIPRO MEDICAL CORPORATION: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. NIPRO MEDICAL CORPORATION: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. NIPRO MEDICAL CORPORATION: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. MEIJI SEIKA PHARMA CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. MEIJI SEIKA PHARMA CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. MEIJI SEIKA PHARMA CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. TOWA PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. TOWA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. TOWA PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. HIKARI PHARMACEUTICAL CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. HIKARI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. HIKARI PHARMACEUTICAL CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. FUJI PHARMA CO., LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. FUJI PHARMA CO., LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. FUJI PHARMA CO., LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 61. MYLAN N.V.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 62. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 63. MYLAN N.V.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 64. GLAXOSMITHKLINE PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 66. GLAXOSMITHKLINE PLC.: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Japan Generic Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved